Dicerna Pharmaceuticals Inc.'s $60 million series C round last week attracted a syndicate of crossover investors that could usher the second-generation RNAi play to a public listing by this time next year.

New investor RA Capital led the round with participation from two other crossover investors - Brookside Capital and Deerfield Capital - as well as Omega Funds. Existing investors Abingworth, Domain Associates, Oxford Bioscience Partners, Skyline Ventures and SR One also participated.